Published in Lancet Oncol on June 06, 2012
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth (2013) 2.70
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst (2014) 2.28
Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62
Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology (2015) 1.42
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med (2015) 1.37
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2016) 1.33
Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res (2012) 1.27
Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol (2013) 1.16
Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One (2013) 1.16
Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol (2013) 1.14
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Separation of tumor cells with dielectrophoresis-based microfluidic chip. Biomicrofluidics (2013) 1.04
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci U S A (2013) 1.02
Future directions for the early detection of recurrent breast cancer. J Cancer (2014) 0.95
Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model. PLoS One (2013) 0.94
Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol (2013) 0.94
Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer (2013) 0.94
Detection of cancer before distant metastasis. BMC Cancer (2013) 0.94
CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med (2014) 0.94
Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget (2015) 0.93
Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer (2015) 0.93
Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther (2014) 0.92
No evidence for shedding of circulating tumor cells to the peripheral venous blood as a result of mammographic breast compression. Breast Cancer Res Treat (2013) 0.91
Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System. PLoS One (2015) 0.90
MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin. Oncotarget (2015) 0.90
Translating metastasis-related biomarkers to the clinic--progress and pitfalls. Nat Rev Clin Oncol (2013) 0.88
Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med (2012) 0.88
Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer. BMC Cancer (2015) 0.87
Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J Thorac Oncol (2014) 0.86
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res (2016) 0.86
Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo. Onco Targets Ther (2014) 0.86
Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer (2014) 0.86
International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res (2014) 0.86
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol (2016) 0.86
Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. J Cancer Res Clin Oncol (2013) 0.85
Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential. PLoS One (2014) 0.84
Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Nat Rev Clin Oncol (2016) 0.84
Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients. PLoS One (2014) 0.83
Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer. PLoS One (2013) 0.83
Development of a new rapid isolation device for circulating tumor cells (CTCs) using 3D palladium filter and its application for genetic analysis. PLoS One (2014) 0.83
Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer. Cancers (Basel) (2013) 0.83
Circulating tumor cells in breast cancer. J Carcinog (2014) 0.83
Promoting quality and evidence-based care in early-stage breast cancer follow-up. J Natl Cancer Inst (2014) 0.82
Heterogeneity of circulating epithelial tumour cells from individual patients with respect to expression profiles and clonal growth (sphere formation) in breast cancer. Ecancermedicalscience (2013) 0.82
Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer. BMC Cancer (2015) 0.82
IFN-γ Rα is a key determinant of CD8+ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. PLoS One (2013) 0.82
Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis. Cancers (Basel) (2013) 0.82
Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study. Int J Breast Cancer (2013) 0.82
Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development. Cell Rep (2015) 0.82
Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat (2014) 0.82
Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget (2016) 0.81
Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. J Invest Dermatol (2015) 0.81
Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. Int J Colorectal Dis (2014) 0.81
Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol (2014) 0.81
A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. Clin Breast Cancer (2013) 0.81
Current Understanding of Circulating Tumor Cells - Potential Value in Malignancies of the Central Nervous System. Front Neurol (2015) 0.80
New and emerging factors in tumorigenesis: an overview. Cancer Manag Res (2015) 0.80
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer (2016) 0.80
Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res (2015) 0.79
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer (2015) 0.79
Sampling circulating tumor cells for clinical benefits: how frequent? J Hematol Oncol (2015) 0.78
Aromatase inhibitors-induced bone loss in early breast cancer. Bonekey Rep (2012) 0.78
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget (2016) 0.78
Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake? Sci Rep (2016) 0.78
(99m)Tc-dextran lymphoscintigraphy can detect sentinel lymph node in breast cancer patients. Exp Ther Med (2014) 0.78
Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence. Front Oncol (2016) 0.78
Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiol Biomarkers Prev (2016) 0.77
Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer. Biomed Res Int (2014) 0.77
Monitoring disease progression and treatment efficacy with circulating tumor cells in esophageal squamous cell carcinoma: A case report. World J Gastroenterol (2015) 0.77
Skeletal manifestations of treatment of breast cancer. Curr Osteoporos Rep (2013) 0.77
Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients. Cancer Res Treat (2015) 0.77
Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets. J Cancer Res Clin Oncol (2016) 0.77
Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells. PLoS One (2013) 0.77
CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. BMC Cancer (2016) 0.77
Detection and quantitation of circulating tumor cell dynamics by bioluminescence imaging in an orthotopic mammary carcinoma model. PLoS One (2014) 0.77
Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer. Geburtshilfe Frauenheilkd (2015) 0.77
The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization. Curr Breast Cancer Rep (2014) 0.76
Circulating tumour cells as biomarkers in early breast cancer. Lancet Oncol (2012) 0.76
Comparison of analytic performances of Cellsearch and iFISH approach in detecting circulating tumor cells. Oncotarget (2017) 0.76
The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biol Med (2016) 0.76
Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study. Melanoma Res (2015) 0.76
EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low. Oncotarget (2015) 0.76
Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst (2015) 0.75
Point of care assessment of melanoma tumor signaling and metastatic burden from μNMR analysis of tumor fine needle aspirates and peripheral blood. Nanomedicine (2016) 0.75
Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer. EBioMedicine (2016) 0.75
Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients. Oncotarget (2017) 0.75
Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. Oncotarget (2016) 0.75
Sodium phenylbutyrate antagonizes prostate cancer through the induction of apoptosis and attenuation of cell viability and migration. Onco Targets Ther (2016) 0.75
Prognostic value of circulating tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma. Onco Targets Ther (2017) 0.75
Notes for developing a molecular test for the full characterization of circulating tumor cells. Chin J Cancer Res (2015) 0.75
Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget (2016) 0.75
Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack. Int J Mol Sci (2016) 0.75
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. BMC Cancer (2016) 0.75
Analysis of circulating tumor cells in breast cancer. J Natl Compr Canc Netw (2013) 0.75
The role of surgeons in building a personalized medicine program. J Surg Oncol (2014) 0.75
Circulating tumour cells in early breast cancer. Lancet Oncol (2012) 0.75
Detection of Methylated Circulating DNA as Noninvasive Biomarkers for Breast Cancer Diagnosis. J Breast Cancer (2017) 0.75
Bone marrow micrometastases in early breast cancer-30-year outcome. Br J Cancer (2016) 0.75
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22
Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol (2008) 3.49
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics (2005) 2.81
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant (2011) 2.63
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ (2002) 2.53
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin (2010) 2.45
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol (2012) 2.40
Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene (2005) 2.34
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer (2003) 2.29
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol (2006) 2.23
Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer (2002) 2.21
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol (2008) 2.17
Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg (2011) 2.16
Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol (2010) 2.12
Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study. Plast Reconstr Surg (2016) 2.05
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer (2003) 2.01
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol (2004) 2.00
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res (2007) 1.94
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol (2011) 1.93
Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol (2007) 1.92
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer (2010) 1.90
Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg (2009) 1.89
Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem (2003) 1.88
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg (2007) 1.86
Squamous cell carcinoma of the breast. J Clin Oncol (2005) 1.83
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood (2010) 1.82
Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg (2003) 1.81
A management algorithm and practical oncoplastic surgical techniques for repairing partial mastectomy defects. Plast Reconstr Surg (2008) 1.81
Determining the optimal approach to breast reconstruction after partial mastectomy. Plast Reconstr Surg (2006) 1.80
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol (2003) 1.74
Mammary angiosarcomas: imaging findings in 24 patients. Radiology (2007) 1.73
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol (2006) 1.72
Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol (2008) 1.71
Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg (2002) 1.70
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2010) 1.70
ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol (2009) 1.70
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg (2006) 1.70
The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle (2003) 1.66
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer (2011) 1.66
Delayed-immediate breast reconstruction. Plast Reconstr Surg (2004) 1.66
Advances in breast conservation therapy. J Clin Oncol (2005) 1.64
Breast cancer metastasis: challenges and opportunities. Cancer Res (2009) 1.63
Predicting the extent of nodal disease in early-stage breast cancer. Ann Surg Oncol (2014) 1.63
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int (2013) 1.63
Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol (2004) 1.61
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg (2005) 1.61
CT-guided percutaneous fine-needle aspiration biopsy of small (< or =1-cm) pulmonary lesions. Radiology (2002) 1.59
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A (2008) 1.54
Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer (2007) 1.54
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol (2004) 1.52
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys (2002) 1.51
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.51
Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol (2003) 1.50
Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer (2005) 1.50
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res (2009) 1.48
A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. Plast Reconstr Surg (2011) 1.48
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer (2007) 1.46
Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol (2003) 1.45
Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer (2005) 1.45
Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol (2010) 1.45
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol (2011) 1.44
Neurocognitive function before and after surgery for insular gliomas. J Neurosurg (2011) 1.44
Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol (2011) 1.43
Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg (2011) 1.42
Inflammatory breast cancer: what we know and what we need to learn. Oncologist (2012) 1.41
Novel treatment for desmoplastic small round cell tumor: hyperthermic intraperitoneal perfusion. J Pediatr Surg (2010) 1.40